/PRZWT/Guangzhou, February 8, 2025 - Public information shows that as of the close of December 27, 2024, Pien Tze Huang Company continued to lead the TOP10 class A share traditional Chinese medicine enterprises with a market value of 132 billion yuan. It is the only two traditional Chinese medicine enterprises with a market value of over 100 billion yuan. The company's overall momentum is good. On January 23, 2025, Pien Tze Huang Company released its 2024 annual performance report. During the reporting period, it achieved operating income of 10.769 billion yuan, an increase of 7.06% year-on-year; net profit attributable to the parent reached 2.974 billion yuan, an increase of 6.32% year-on-year.
Sales Changhong, product matrix diversified pilot
As a traditional proprietary Chinese medicine full of legend and cultural heritage, Pien Tze Huang has become a high-quality Chinese medicine product trusted by consumers with its unique formula and exquisite craftsmanship, and has been praised at home and abroad.
In recent years, Pien Tze Huang Company has continued to adjust its product structure. With the blessing of Pien Tze Huang and Pien Tze Huang Capsules, the sales data has been singing all the way. While consolidating the advantages of core products, Pien Tze Huang Company is also committed to expanding its product line. Pien Tze Huang Brand Angong Niuhuang Pills, the market share of cardiovascular and cerebrovascular drugs represented by the product, has steadily increased. It will break through 100 million yuan in 2022, about 266 million yuan in 2023, and 300 million yuan in 2024. The potential should not be underestimated.
In addition, Pien Tze Huang Company continues to expand and strengthen its range of drugs, such as Dangan Pinggan Capsules, Compound Pien Tze Huang Barefoot Tablets, and Compound Pien Tze Huang Ointment, constantly enriching its product line, and actively promoting industrial diversification and product diversification development at the same time. It expands the territory of the big health industry and focuses on cosmetics, daily chemicals, health food and other fields. It organically combines traditional Chinese medicine culture with modern health culture and beauty fashion culture to create hot-selling products and broaden the audience of Pien Tze Huang brand.
Fruits and branches, new drug research and development achievements are remarkable
The increasing enrichment of the product line is due to the high-intensity investment in R & D and innovation of Pien Tze Huang Company. In 2024, Pien Tze Huang Company will focus on the secondary development and research of Pien Tze Huang and other advantageous varieties, accelerate the promotion of new Product Research & Development such as innovative medicines of traditional Chinese medicine, classic famous prescriptions, and innovative medicines of chemical medicines, and empower enterprises with high-quality development through technology.
Pien Tze Huang Company, as a national technology innovation demonstration enterprise, a national high-tech enterprise, and a national intellectual property demonstration enterprise, is committed to deepening cooperation with domestic and foreign institutions and research institutes, academicians and expert teams, and jointly promoting the transformation of various clinical research and R & D results.
Pien Tze Huang Company has undertaken the construction of the special project "Belt and Road Initiative" of the State Administration of Traditional Chinese Medicine for international cooperation in traditional Chinese medicine, the project "Famous Proprietary Chinese Medicine International Industry Collaboration Base", and the University of Macau, Hong Kong Baptist University, etc. to build a scientific research platform to promote the establishment of the Chinese Academy of Engineering Academician and Chinese Medicine Master Wang Qi Academician Workstation in the company.
In 2024, Pien Tze Huang Company successively established the "Peking University Medicine - Pien Tze Huang Traditional Chinese Medicine Pharmaceutical Efficacy Substance Research Joint Laboratory" with the Peking University Medical Department, the "Traditional Chinese Medicine Intelligent Manufacturing Platform" with Beijing University of Traditional Chinese Medicine, and the "Traditional Chinese Medicine Small RNA Function and Application Research Joint Center" with Nanjing University to carry out traditional Chinese medicine microRNA research, carry out a number of proprietary Chinese medicine action mechanism and pharmacological efficacy research, and jointly promote the inheritance and innovation of traditional Chinese medicine.
Glory plus body, branding results
Looking back on 2024, Pien Tze Huang's industry influence has become increasingly prominent, winning numerous industry authoritative awards, including "2024 Foreigners' Favorite Chinese Brand" and "Like 2024 My Favorite Chinese Brand".
The increasing brand value year by year has helped Pien Tze Huang to be crowned "2024 China's Top 500 Brands", GYBrand's global brand "China's Top 500 Most Valuable Brands", the third place in the "2024 Health Industry Brand Value List", and the top ten in the Brand Finance "China's Most Valuable Pharmaceutical Brands List". With 42.289 billion yuan, it ranked second in the China Time-honored Brand List. It has topped the "Hurun Brand List China's Medical and Health Brand Value List" for four consecutive years, and has topped the "2024 Hurun China's Most Historical and Cultural Heritage Brands List" for three consecutive years.
Recently, Pien Tze Huang was selected for the China Brand Forum "2024 China Brand Innovation Case" "2024 Party Building Leading Time-honored Brand High-Quality Development Case", obtained the China-US Friendly Exchange Partner Certificate of the Guling Forum, and was selected for the 2024 People's Quality Development Forum and People's Ingenuity Brand Promotion and Display Activity "People's Ingenuity Brand", once again demonstrating the brand value.
Pien Tze Huang's strong brand strength has allowed Pien Tze Huang to gain a firm foothold in the market, and his comprehensive strength has also been highly praised by capital markets and other dimensions. Pien Tze Huang won the 2023 "Golden Bull Most Investment Value Award", the 2024 "The 18th Main board Listed Company Value Top 100 Award", the 2024 "China Pharmaceutical Listed Company ESG Competitiveness TOP20", the 2024 "Listed Company ESG Value Transfer Award", the 2024 "Listed Company Word of Mouth List Special Category List" Listed Company 20-Year Leading Enterprise Award, and the 2024 "Most Popular Listed Company TOP300", demonstrating extraordinary strength.
On December 27, 2024, the "Excellent Entrepreneur" title was awarded to Pien Tze Huang Company at the "SSE Gold Quality" award ceremony at the SSE Dishui Lake Listed Company High Quality Development Conference.
Looking forward to 2025, Pien Tze Huang Company will adhere to the development concept of "maintaining integrity and innovation, walking steadily and going far", and continue to make efforts in business expansion, R & D innovation, branding and other aspects. In the field of medicine, strengthen core product advantages, broaden the market territory of a series of drugs, and introduce new products in cosmetics, daily chemicals, health food and other fields to meet diverse needs, so as to help the layout of the big health industry. In the field of research and development, increase innovation efforts, accelerate the progress of new drug research and development, deepen cooperation between industry, university and research, and unlock more medical mysteries.
In terms of branding, we will continue to deepen our series of cooperation with authoritative media, Qiu Qiyuan and other sports stars, actively participate in industry events, leverage new media platforms, and expand the influence of Pien Tze Huang through multi-point linkage, continuing to write a glorious chapter in the field of traditional Chinese medicine.
